Edwards Lifesciences Corporation

WBAG:EWLS Stock Report

Market Cap: €39.9b

Edwards Lifesciences Valuation

Is EWLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EWLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EWLS (€68.33) is trading above our estimate of fair value (€67.91)

Significantly Below Fair Value: EWLS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EWLS?

Key metric: As EWLS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EWLS. This is calculated by dividing EWLS's market cap by their current earnings.
What is EWLS's PE Ratio?
PE Ratio27.1x
EarningsUS$1.57b
Market CapUS$42.20b

Price to Earnings Ratio vs Peers

How does EWLS's PE Ratio compare to its peers?

The above table shows the PE ratio for EWLS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.4x
GEHC GE HealthCare Technologies
22.6x11.4%US$37.7b
IDXX IDEXX Laboratories
39.9x9.8%US$34.2b
300760 Shenzhen Mindray Bio-Medical Electronics
26.3x14.7%CN¥325.4b
RMD ResMed
32.9x11.1%US$36.7b
EWLS Edwards Lifesciences
27.1x1.9%€42.2b

Price-To-Earnings vs Peers: EWLS is good value based on its Price-To-Earnings Ratio (27.1x) compared to the peer average (30.4x).

Price to Earnings Ratio vs Industry

How does EWLS's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
EWLS 27.1xIndustry Avg. 29.8xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EWLS is good value based on its Price-To-Earnings Ratio (27.1x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is EWLS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EWLS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EWLS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EWLS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€68.33
€72.51
+6.1%
9.8%€91.62€59.63n/a28
Nov ’25€63.02
€70.59
+12.0%
9.8%€89.49€58.24n/a28
Oct ’25€59.62
€70.16
+17.7%
9.6%€87.45€58.72n/a27
Sep ’25€63.28
€75.22
+18.9%
11.1%€93.67€60.03n/a27
Aug ’25€57.39
€75.22
+31.1%
11.1%€93.67€60.03n/a27
Jul ’25€85.35
€89.50
+4.9%
10.2%€99.70€65.23n/a27
Jun ’25€80.10
€89.15
+11.3%
9.6%€98.80€67.41n/a28
May ’25€79.82
€88.96
+11.4%
9.5%€97.93€68.09n/a28
Apr ’25€88.28
€85.85
-2.8%
9.2%€97.34€66.74n/a28
Mar ’25€78.50
€84.46
+7.6%
8.3%€97.15€66.61n/a28
Feb ’25€72.22
€73.64
+2.0%
12.3%€88.32€52.44n/a28
Jan ’25€69.38
€72.36
+4.3%
12.3%€87.25€51.81n/a28
Dec ’24€62.60
€73.02
+16.6%
14.4%€92.85€51.89n/a28
Nov ’24€59.90
€77.07
+28.7%
13.8%€96.52€59.62€63.0227
Oct ’24€66.02
€90.48
+37.1%
8.8%€104.05€70.94€59.6226
Sep ’24€70.76
€87.49
+23.6%
8.8%€100.16€68.29€63.2824
Aug ’24€74.38
€87.49
+17.6%
8.8%€100.16€68.29€57.3924
Jul ’24€86.14
€87.06
+1.1%
8.5%€97.59€67.85€85.3523
Jun ’24€78.68
€87.06
+10.7%
8.5%€97.59€67.85€80.1023
May ’24€78.02
€84.15
+7.9%
8.7%€95.29€66.25€79.8222
Apr ’24€75.74
€80.09
+5.7%
9.6%€92.25€61.81€88.2822
Mar ’24€74.51
€83.62
+12.2%
13.5%€121.10€62.41€78.5022
Feb ’24€72.09
€80.64
+11.9%
14.1%€118.34€60.08€72.2222
Jan ’24€70.39
€85.99
+22.2%
16.0%€122.43€64.04€69.3823
Dec ’23€74.06
€90.55
+22.3%
13.8%€123.50€69.35€62.6022
Nov ’23€72.51
€96.83
+33.5%
13.4%€130.47€78.28€59.9023

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

CVS Health

US$74.3b

Provides health solutions in the United States.

CVS

US$56.72

7D

4.9%

1Y

-8.8%

DENTSPLY SIRONA

US$3.8b

Manufactures and sells various dental products and technologies worldwide.

XRAY

US$18.54

7D

4.7%

1Y

-35.4%

Hologic

US$18.3b

Develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.

HOLX

US$75.50

7D

2.0%

1Y

18.0%